12/22
07:42 pm
abvx
Why Abivax Stock Was on Fire Today [Yahoo! Finance]
Low
Report
Why Abivax Stock Was on Fire Today [Yahoo! Finance]
12/18
04:05 pm
abvx
Abivax to be Added to Nasdaq Biotechnology Index
Low
Report
Abivax to be Added to Nasdaq Biotechnology Index
12/18
09:03 am
abvx
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/17
04:05 pm
abvx
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
Low
Report
Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings
12/16
04:06 pm
abvx
Abivax (NASDAQ:ABVX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Abivax (NASDAQ:ABVX) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/16
08:05 am
abvx
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Citizens Jmp from $114.00 to $131.00. They now have a "market outperform" rating on the stock.
Low
Report
Abivax (NASDAQ:ABVX) had its price target raised by analysts at Citizens Jmp from $114.00 to $131.00. They now have a "market outperform" rating on the stock.
12/16
07:09 am
abvx
Abivax (NASDAQ:ABVX) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Abivax (NASDAQ:ABVX) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/15
04:07 pm
abvx
Abivax Presents Third Quarter 2025 Financial Results
Medium
Report
Abivax Presents Third Quarter 2025 Financial Results
12/13
01:10 am
abvx
Medium
Report
11/24
09:04 am
abvx
Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
Medium
Report
Abivax (NASDAQ:ABVX) was given a new $140.00 price target on by analysts at Truist Financial Corporation.
11/24
08:43 am
abvx
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Medium
Report
Abivax (NASDAQ:ABVX) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
11/7
06:19 am
abvx
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
Low
Report
Abivax (NASDAQ:ABVX) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.
11/5
07:02 pm
abvx
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Medium
Report
Abivax (NASDAQ:ABVX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
11/4
07:21 am
abvx
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
Low
Report
Abivax (NASDAQ:ABVX) had its "market outperform" rating reaffirmed by analysts at Citigroup Inc..
11/3
04:05 pm
abvx
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
Low
Report
Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis
10/13
07:04 am
abvx
Abivax (NASDAQ:ABVX) was given a new $142.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
Low
Report
Abivax (NASDAQ:ABVX) was given a new $142.00 price target on by analysts at Barclays PLC. They now have an "overweight" rating on the stock.
10/10
07:19 am
abvx
Abivax (NASDAQ:ABVX) was given a new $150.00 price target on by analysts at Guggenheim.
Low
Report
Abivax (NASDAQ:ABVX) was given a new $150.00 price target on by analysts at Guggenheim.
10/6
05:02 pm
abvx
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at BTIG Research.
Low
Report
Abivax (NASDAQ:ABVX) had its "buy" rating reaffirmed by analysts at BTIG Research.
10/6
04:00 am
abvx
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
Low
Report
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies
10/5
11:00 am
abvx
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
Medium
Report
Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data
10/3
02:37 pm
abvx
Abivax (NASDAQ:ABVX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Abivax (NASDAQ:ABVX) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
9/29
04:05 pm
abvx
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting
Low
Report
Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting